文献速递哮喘

固定剂量皮下瑞利珠单抗对重症未控制哮喘急性发作及口服糖皮质激素减量的影响:两项3期随机双盲安慰剂对照试验结果

Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
PubMed 文献 · Lancet Respir Med · 2020-02-14

两项3期随机双盲安慰剂对照试验评估皮下注射瑞利珠单抗110 mg每4周一次在重症未控制哮喘患者中的疗效。

要点

  • 皮下瑞利珠单抗110 mg未能降低整体重症未控制哮喘患者的急性发作率。
  • 血嗜酸性粒细胞≥400 cells/μL亚组中皮下瑞利珠单抗可降低发作频率。
  • 口服糖皮质激素依赖患者中皮下瑞利珠单抗110 mg未能实现激素减量。

核心结论

  • 固定剂量皮下瑞利珠单抗110 mg对血嗜酸性粒细胞≥300 cells/μL的重症未控制哮喘患者未能减少急性发作频率。
  • 该剂量对口服糖皮质激素依赖的重症嗜酸性哮喘患者未能减少每日维持口服糖皮质激素剂量。
  • 达到最大疗效可能需要高于110 mg皮下给药所观察到的暴露量。

研究设计与样本

  • 两项随机、双盲、安慰剂对照的3期研究。
  • 研究1纳入468例重症未控制哮喘患者,随机1:1接受皮下瑞利珠单抗110 mg(n=236)或安慰剂(n=232),每4周一次,共52周。
  • 研究2纳入177例口服糖皮质激素依赖的重症哮喘患者,随机1:1接受皮下瑞利珠单抗110 mg(n=88)或安慰剂(n=89),每4周一次,共24周。

主要发现

  • 两项研究中瑞利珠单抗的不良事件和严重不良事件频率与安慰剂相似。

关键数值与推荐

  • 研究1入组标准:重症未控制哮喘、既往一年≥2次急性发作、血嗜酸性粒细胞≥300 cells/μL(嗜酸性粒细胞<400 cells/μL者不超过30%)、至少中等剂量吸入糖皮质激素联合≥1种其他哮喘控制药物。
  • 研究2入组标准:重症哮喘、血嗜酸性粒细胞≥300 cells/μL、每日维持口服糖皮质激素(泼尼松5-40 mg或等效剂量)、高剂量吸入糖皮质激素联合另一种控制药物。

临床怎么用

  • 皮下瑞利珠单抗110 mg固定剂量不适用于整体重症未控制哮喘人群的急性发作预防。
  • 对于血嗜酸性粒细胞≥400 cells/μL的重症哮喘患者,皮下瑞利珠单抗110 mg可能降低急性发作频率。
  • 口服糖皮质激素依赖的重症嗜酸性哮喘患者不应使用皮下瑞利珠单抗110 mg进行激素减量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Reslizumab 3 mg/kg administered intravenously is approved for the treatment of severe eosinophilic asthma. We assessed the safety and efficacy of subcutaneous reslizumab 110 mg in two trials in patients with uncontrolled severe asthma and increased blood eosinophils. The aim was to establish whether subcutaneous reslizumab 110 mg can reduce exacerbation rates in these patients (study 1) or reduce maintenance oral corticosteroid dose in patients with corticosteroid-dependent asthma (study 2). METHODS: Both studies were randomised, double-blind, placebo-controlled, phase 3 studies. Entry criteria for study 1 were uncontrolled severe asthma, two or more asthma exacerbations in the previous year, a blood eosinophil count of 300 cells per μL or more (including no more than 30% patients with an eosinophil count <400 cells/μL), and at least a medium dose of inhaled corticosteroids with one or more additional asthma controllers. Patients in study 2 had severe asthma, a blood eosinophil count of 300 cells per μL or more, daily maintenance oral corticosteroid (prednisone 5-40 mg, or equivalent), and high-dose inhaled corticosteroids plus another controller. Patients were randomly assigned (1:1) to subcutaneous reslizumab (110 mg) or placebo once every 4 weeks for 52 weeks in study 1 and 24 weeks in study 2. Patients and investigators were masked to treatment assignment. Primary efficacy outcomes were frequency of exacerbations during 52 weeks in study 1 and categorised percentage reduction in daily oral corticosteroid dose from baseline to weeks 20-24 in study 2. Primary efficacy analyses were by intention to treat, and safety analyses included all patients who received at least one dose of study treatment. These studies are registered with ClinicalTrials.gov, NCT02452190 (study 1) and NCT02501629 (study 2). FINDINGS: Between Aug 12, 2015, and Jan 31, 2018, 468 patients in study 1 were randomly assigned to placebo (n=232) or subcutaneous reslizumab (n=236), and 177 in study 2 to placebo (n=89) or subcutaneous reslizumab (n=88). In study 1, we found no significant difference in the exacerbation rate between reslizumab and placebo in the intention-to-treat population (rate ratio 0·79, 95% CI 0·56-1·12; p=0·19). Subcutaneous reslizumab reduced exacerbation frequency compared with placebo in the subgroup of patients with blood eosinophil counts of 400 cells per μL or more (0·64, 95% CI 0·43-0·95). Greater reductions in annual exacerbation risk (p=0·0035) and longer time to first exacerbation were observed for patients with higher trough serum reslizumab concentrations. In study 2, we found no difference between placebo and fixed-dose subcutaneous reslizumab in categorised percentage reduction in daily oral corticosteroid dose (odds ratio for a lower category of oral corticosteroid use in the reslizumab group vs the placebo group, 1·23, 95% CI 0·70-2·16; p=0·47). The frequency of adverse events and serious adverse events with reslizumab were similar to those with placebo in both studies. INTERPRETATION: Fixed-dose (110 mg) subcutaneous reslizumab was not effective in reducing exacerbation frequency in patients with uncontrolled asthma and increased blood eosinophils (≥300 cells/μL), or in reducing the daily maintenance oral corticosteroid dose in patients with oral corticosteroid-dependent severe eosinophilic asthma. Higher exposures than those observed with 110 mg subcutaneous reslizumab are required to achieve maximal efficacy. FUNDING: Teva Branded Pharmaceutical Products R&D.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Bernstein JA, Virchow JC, Murphy K, et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2020. PMID: 32066536. doi:10.1016/S2213-2600(19)30372-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。